Inflammation and Depression in People With HIV
NCT05849038
This study is recruiting at 2 US sites in 1 state, according to its ClinicalTrials.gov record last updated .
Summary
The purpose of this 10-week, double-blind, placebo-controlled study is to determine whether inflammation impacts reward and motor neural circuitry to contribute to depressive symptoms like anhedonia and psychomotor slowing in people with Human Immunodeficiency Virus (HIV) and depression. Sixty male and female patients with HIV who have depression, anhedonia and high inflammation and are stable on effective treatment for their HIV will be randomized to receive either the anti-inflammatory drug baricitinib or a placebo for 10 weeks.
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- HIV
- Depression
- Anhedonia
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 2
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Emory University
- Last updated on ClinicalTrials.gov
- May 28, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Georgia · 2
- Emory University Hospital · Atlanta, GA
- Grady Memorial Hospital · Atlanta, GA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.